NEW YORK – Seer reported after the close of market Monday that its Q4 revenues grew nearly sixfold year over year.
The company also announced on Monday that it has signed a non-exclusive commercial agreement with Sciex to provide complete workflows combining Seer's Proteograph proteomics platform with Sciex's mass spectrometers. The deal follows similar agreements with Bruker and Thermo Fisher Scientific.